Summary Points
The International Health Regulations(2005) are the overarching framework to ensure global public health security and provide the basis for this work. The WHO Best Practices for Sharing Influenza Virus and Sequence Data document provides guidance, and conclusions from recent discussions and meetings can assist in attaining a goal that is internationally agreed upon: to improve access to H5N1 and pandemic vaccines as a means, among others, to strengthen pandemic preparedness.
The current meeting focused on feasibility of vaccine stockpiles to complement production capacity building efforts.
Scientific evidence and political will indicate that vaccine stockpiles may be feasible.
- H5N1 vaccines have been shown to be safe and immunogenic .
- New data suggest lower antigen doses and cross protection are realistic expectations.
- Based on scientific evidence reviewed, SAGE has recommended that WHO proceed to assess the feasibility of H5N1 vaccine stockpiles.
- Realizing its potential, the Developing Country Vaccine Manufacturers Network has indicated its commitment to work on its mission with WHO and its Member States.
- The International Federation of Pharmaceutical Manufacturers Association has indicated the same commitment and forecasts increasing manufacturing capacity in the next 3 to 5 years to meet potential growing demand.
- Some Member States expressed commitment to work with WHO.
Next steps
Agree on the need to now focus on the details about how to create, maintain, fund and use such an H5N1 vaccine stockpile resource.
WHO will continue to consult with appropriate partners and Member States on the development of mechanisms for broader access to pandemic vaccines.